Skip to main content

Lung function trajectories in patients with idiopathic pulmonary fibrosis.

Publication ,  Journal Article
Neely, ML; Hellkamp, AS; Bender, S; Todd, JL; Liesching, T; Luckhardt, TR; Oldham, JM; Raj, R; White, ES; Palmer, SM
Published in: Respir Res
August 24, 2023

BACKGROUND: Idiopathic pulmonary fibrosis (IPF) is a progressive fibrosing interstitial lung disease characterised by decline in lung function. We evaluated trajectories of forced vital capacity (FVC) and diffusing capacity (DLco) in a cohort of patients with IPF. METHODS: Patients with IPF that was diagnosed or confirmed at the enrolling centre in the previous 6 months were enrolled into the IPF-PRO Registry between June 2014 and October 2018. Patients were followed prospectively, with lung function data collected as part of routine clinical care. Mean trajectories of FVC and DLco % predicted in all patients and in subgroups by characteristics assessed at enrolment were estimated using a joint model that accounted for factors such as disease severity and visit patterns. RESULTS: Of 1002 patients in the registry, 941 had ≥ 1 FVC and/or DLco measurement after enrolment. The median (Q1, Q3) follow-up period was 35.1 (18.9, 47.2) months. Overall, mean estimated declines in FVC and DLco % predicted were 2.8% and 2.9% per year, respectively. There was no evidence that the mean trajectories of FVC or DLco had a non-linear relationship with time at the population level. Patients who were male, white, had a family history of ILD, were using oxygen, or had prior/current use of antifibrotic therapy at enrolment had greater rates of decline in FVC % predicted. Patients who were male or white had greater rates of decline in DLco % predicted. CONCLUSIONS: Data from the IPF-PRO Registry suggest a constant rate of decline in lung function over a prolonged period, supporting the inexorably progressive nature of IPF. A graphical abstract summarising the data in this manuscript is available at: https://www.usscicomms.com/respiratory/IPF-PRORegistry_LungFunctionTrajectories . TRIAL REGISTRATION: NCT01915511.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

Respir Res

DOI

EISSN

1465-993X

Publication Date

August 24, 2023

Volume

24

Issue

1

Start / End Page

209

Location

England

Related Subject Headings

  • Respiratory System
  • Registries
  • Patient Acuity
  • Oxygen
  • Male
  • Lung
  • Idiopathic Pulmonary Fibrosis
  • Humans
  • Female
  • 3202 Clinical sciences
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Neely, M. L., Hellkamp, A. S., Bender, S., Todd, J. L., Liesching, T., Luckhardt, T. R., … Palmer, S. M. (2023). Lung function trajectories in patients with idiopathic pulmonary fibrosis. Respir Res, 24(1), 209. https://doi.org/10.1186/s12931-023-02503-5
Neely, Megan L., Anne S. Hellkamp, Shaun Bender, Jamie L. Todd, Timothy Liesching, Tracy R. Luckhardt, Justin M. Oldham, Rishi Raj, Eric S. White, and Scott M. Palmer. “Lung function trajectories in patients with idiopathic pulmonary fibrosis.Respir Res 24, no. 1 (August 24, 2023): 209. https://doi.org/10.1186/s12931-023-02503-5.
Neely ML, Hellkamp AS, Bender S, Todd JL, Liesching T, Luckhardt TR, et al. Lung function trajectories in patients with idiopathic pulmonary fibrosis. Respir Res. 2023 Aug 24;24(1):209.
Neely, Megan L., et al. “Lung function trajectories in patients with idiopathic pulmonary fibrosis.Respir Res, vol. 24, no. 1, Aug. 2023, p. 209. Pubmed, doi:10.1186/s12931-023-02503-5.
Neely ML, Hellkamp AS, Bender S, Todd JL, Liesching T, Luckhardt TR, Oldham JM, Raj R, White ES, Palmer SM. Lung function trajectories in patients with idiopathic pulmonary fibrosis. Respir Res. 2023 Aug 24;24(1):209.

Published In

Respir Res

DOI

EISSN

1465-993X

Publication Date

August 24, 2023

Volume

24

Issue

1

Start / End Page

209

Location

England

Related Subject Headings

  • Respiratory System
  • Registries
  • Patient Acuity
  • Oxygen
  • Male
  • Lung
  • Idiopathic Pulmonary Fibrosis
  • Humans
  • Female
  • 3202 Clinical sciences